Business context and reporting period
This is Lianluo Smart Limited’s annual Form 20-F for the fiscal year ended December 31, 2019—not a standalone fourth-quarter report. The company, listed on Nasdaq as LLIT, focuses on medical devices and obstructive sleep apnea (OSAS) diagnostic products and services in China. The filing’s “Newegg Commerce, Inc.” metadata does not match the registrant identified in the filing.
Key financial metrics
Amounts are in U.S. dollars unless noted.
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $383,458 | $559,386 |
| Gross loss / gross margin | $(360,286) / approximately -94% | $(198,515) / approximately -36% |
| Operating loss | $(3,802,375) | $(9,260,817) |
| Net loss | $(4,450,994) | $(8,910,002) |
| Net loss per share, basic and diluted | $(0.25) | $(0.51) |
| Cash used in operating activities | $(1,670,903) | $(3,629,567) |
| Cash and cash equivalents at year-end | $22,834 | $477,309 |
| Working capital | $(1,555,999) | $1,260,558 |
| Total assets | $2,333,953 | $5,698,670 |
| Total liabilities | $3,622,742 | $2,582,050 |
| Shareholders’ equity (deficit) | $(1,288,789) | $3,116,620 |
Revenue comprised $212,394 of product sales and $171,064 of OSAS diagnostic services. The company reported $1,208,331 in short-term related-party borrowings at year-end, all current; $931,450 was owed to controlling shareholder Hangzhou Lianluo. It reported no capital expenditures in 2019. The filing identifies substantial doubt about the company’s ability to continue as a going concern.
Material changes versus prior period
- Revenue fell 31% year over year, primarily as product sales declined by about $130,000. OSAS service revenue also declined, from $217,042 to $171,064.
- Gross loss widened despite a modest reduction in cost of revenue, as revenue fell while significant costs—especially depreciation and amortization—remained.
- Operating loss narrowed 59%, principally reflecting lower selling and administrative expenses and no repeat of the 2018 $3.28 million intangible-asset impairment.
- Net loss improved, but included a $1.36 million unrealized loss on marketable securities, partly offset by a $740,000 non-cash gain from the change in fair value of warrant liabilities.
- Operating cash outflow decreased to $1.67 million from $3.63 million, but cash at year-end fell sharply. The company’s equity position moved from positive to a deficit.
Outlook, risks, contingencies and unusual items
- Liquidity and funding: Management said approximately $7.2 million of net proceeds from February–March 2020 equity financings, together with cost reductions, were expected to cover working-capital needs for the next 12 months. The financing issued 10.9 million Class A shares alongside warrants, creating material potential dilution. Management cautioned that further funding may be needed.
- COVID-19: China operating restrictions and hospital/check-up-center closures sharply reduced service activity in January–February 2020; product sales were also disrupted. Operations and customer sites had only partially resumed by the filing date. The company said the full impact on 2020 results and liquidity could not be estimated.
- Restructuring and legal matters: More than 50 employees were laid off in 2019, with further reductions in 2020. Employment claims led to recorded liabilities, and the company disclosed a 2020 settlement of approximately RMB2.44 million (about $349,000). A separate arbitration award ordered payment of approximately $18,700, including fees.
- Operating risks: The business remains loss-making with deeply negative gross margins, dependence on a small product and service base, and significant customer and supplier concentration. One supplier represented 100% of 2019 purchases; the two largest customers represented approximately 36% of revenue.
- Controls and listing: Management concluded internal control over financial reporting and disclosure controls were ineffective due to insufficient qualified U.S. GAAP/SEC-reporting personnel and inadequate review capacity. The company also faced Nasdaq minimum-bid-price compliance risk; its second compliance period was extended to November 20, 2020.
- Governance and ownership: The dual-class structure gives Class B shares ten votes each. Hangzhou Lianluo held the Class B shares and approximately 86% of voting power as reported. The company does not expect to pay dividends in the foreseeable future.
Most important facts for investors to verify
- Confirm the registrant and period: the supplied filing is Lianluo Smart Limited’s 2019 annual report, not a Newegg Commerce filing or a quarterly report.
- Review the going-concern disclosure and whether post-year-end financing and operating cash flows proved sufficient; compare actual cash and working capital after the disclosed offerings.
- Assess whether OSAS service volumes, revenue, and unit economics recovered after COVID-related disruptions, and whether the severe negative gross margin improved.
- Verify the terms, warrant overhang, and fully diluted share count arising from the 2020 financings, including anti-dilution provisions.
- Track related-party loan repayment or extensions, employee settlement payments, supplier concentration, and progress on remediating the material weakness in controls.
- Check subsequent Nasdaq compliance status and any additional listing or financing developments.